NEW YORK, March 26, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding Endocyte, Inc. (NASDAQ: ECYT), Ophthotech Corporation (NASDAQ: OPHT), AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), bluebird bio, Inc. (NASDAQ: BLUE), and Cantel Medical Corp. (NYSE: CMN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Endocyte, Inc. Analyst Notes
On March 21, 2014, Endocyte, Inc. (Endocyte) announced results from its Phase 2b TARGET trial, which showed that the study met the primary endpoint for the combination of vintafolide (EC145/MK-8109) and docetaxel in folate receptor (FR)-positive recurrent non-small cell lung cancer (NSCLC) patients. According to the Company, the data showed that risk of disease worsening or death was reduced by 25% for patients treated with the vintafolide/docetaxel combination versus docetaxel alone. Binh Nguyen, M.D., Ph.D., Vice President of Medical Affairs at Endocyte, stated, "We are pleased with the results of this study, as the vintafolide/docetaxel combination showed meaningful activity in patients with recurrent NSCLC, meeting the primary endpoint of the trial. We were especially pleased with the results in the adenocarcinoma population and early OS trends, and we have learned important information about the dosing schedule. We look forward to reviewing additional analysis of this study when the OS data has matured later this year to help inform potential further development of the vintafolide/docetaxel combination in NSCLC." The full analyst notes on Endocyte, Inc. are available to download free of charge at:
Ophthotech Corporation Analyst Notes
On March 21, 2014, Ophthotech Corporation's (Ophthotech) stock went down by 5.32%, closing at $35.96. However, in the past three months Ophthotech shares went up by 15.93%, compared to the Nasdaq Composite which went up by 4.19% during the same trading period. The full analyst notes on Ophthotech Corporation are available to download free of charge at:
AcelRx Pharmaceuticals, Inc. Analyst Notes
On March 21, 2014, AcelRx Pharmaceuticals, Inc.'s (AcelRx Pharmaceuticals) stock went down by 3.63%, closing at $12.47. Over the past five trading days, the Company's stock went up by 0.16%, compared to the Nasdaq Composite Index which went up by 0.74% during the same trading period. The full analyst notes on AcelRx Pharmaceuticals, Inc. are available to download free of charge at:
bluebird bio, Inc. Analyst Notes
On March 5, 2014, bluebird bio, Inc. (bluebird bio) reported its full-year 2013 financial results. Total revenues for full year 2013 were $20.2 million, compared to total revenues of $0.3 million in full year 2012. Net loss applicable to common stockholders for full year 2013 was $25.3 million or $2.02 per diluted share, compared to full-year 2012 net loss applicable to common stockholders of $3.6 million or $13.79 per diluted share. Commenting on the results, Nick Leschly, Chief bluebird bio, stated, "In 2013 we transplanted the first patients in our phase 2/3 Starbeam study for CCALD and our phase 1/2 HGB-205 study for beta thalassemia and sickle cell disease. This was a considerable accomplishment for all those involved in these studies. Earlier in the year, we leveraged our lentiviral platform, signing a multi-year collaboration with Celgene in the exciting area of CAR T for oncology, which strengthened our balance sheet and further validated our lentiviral platform. In June, we completed a successful IPO, setting the stage for the next evolution in the bluebird story. We look forward to another productive year in 2014." The full analyst notes on bluebird bio, Inc. are available to download free of charge at:
Cantel Medical Corp. Analyst Notes
On March 11, 2014, Cantel Medical Corp. (Cantel Medical) reported its Q2 FY 2014 and H1 FY 2014 (period ended January 31, 2014) financial results. Net sales for Q2 FY 2014 went up by 11.9% YoY to $119.0 million, and H1 FY 2014 net sales went up by 15.2% YoY to $237.3 million. Net income for Q2 FY 2014 was $11.1 million or $0.27 per diluted share, compared to net income of $10.5 million or $0.25 per diluted share in Q2 FY 2013. H1 FY 2014 net income was $22.3 million or $0.54 per diluted share, compared to net income of $20.0 million or $0.49 per diluted share in H1 FY 2013. Commenting on the results, Andrew Krakauer, Cantel Medical's President and CEO, stated, "We are pleased to have delivered record sales and solid earnings performance in the second quarter. These positive results confirm the continued success of our strategic approach to growth which includes investing in new product development, sales and marketing programs and acquisitions." The full analyst notes on Cantel Medical Corp. are available to download free of charge at:
About Analysts Review
We provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Analysts Review in this article or report according to the Procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review